InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,099.34
(
0.33%
)
Post# of 251706
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: oc631 post# 127266

Saturday, 09/24/2011 11:41:45 AM

Saturday, September 24, 2011 11:41:45 AM

Post# of 251706

The lack of FOB program disclosure is industry-wide and the danger lies in too many companies pursuing the same biologic. Which companies are making progress in FOB and which are hitting dead ends? We don't even know what they are working on so it's hard to tell.

It’s a pretty good bet that one of MNTA’s FoB programs is Orencia (#msg-56429332, #msg-52853238, #msg-56471065). Another good bet is that MNTA is working on one or more of the TNF-alpha drugs (#msg-59857407).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up